Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

SABR response rate falls short in early NSCLC

Key clinical point: For patients with resectable stage I non–small cell lung cancer (NSCLC), stereotactic ablative radiotherapy (SABR) may lack the efficacy needed to replace surgical intervention.

Major finding: The pathologic complete response rate (pCR) was 60% for patients treated with neoadjuvant SABR and surgery.

Study details: A phase 2, single-arm study involving 40 patients with stage I NSCLC, of whom 35 were evaluable.

Disclosures: The Ontario Institute for Cancer Research funded the study. Dr. Palma and Dr. Ward are patent holders for a computed tomography technology that assesses responses after radiotherapy. Dr. Louie reported honoraria from AstraZeneca and Varian Medical Systems Inc.

Citation:

Palma et al. 2019 Feb 21. doi: 10.1001/jamaoncol.2018.6993.